Understanding the Toxicity Index: A Superior Measure for Adverse Event Analysis
This video explains the toxicity index—a powerful tool for analyzing and comparing the severity of side effects in patients undergoing treatment. First introduced by André Rogatko in 2004, the toxicity index has become a superior method for summarizing adverse events in clinical trials. What You’ll Learn: * How the toxicity index is calculated by ordering toxicity grades from highest to lowest. Why the index, ranging from 0 to 5.833, offers more nuanced insights than maximum grade or average grade. How the toxicity index identifies dose-limiting toxicity with scores of 3 or higher. Why the toxicity index outperforms other methods in distinguishing treatment toxicity profiles. How to create visual comparisons of the toxicity index, maximum grade, and average grade using patient data.

Center for Cancer Research Focus RT Clinical Trial for Prostate Cancer: Frequently Asked Questions

ProAE R Package: Advanced Tools for Patient-Reported Adverse Event Analysis in Clinical Trials

How Patient-Reported Bother by Side Effects Predicts Cancer Treatment Discontinuation

Introducing the Breast Cancer Symptom Explorer: Visualizing Adverse Events and Quality of Life

Neuro-Oncology Branch Shapes the Next Generation of Researchers and Clinicians

Improving Cancer Care for Older Adults: The Role of Geriatric Assessments

Risk Factors for Cancer | Did You Know?

Lacey Koelling — CCR Patients Perspective

Office of Cancer Survivorship Vision, Mission, and Future

Childhood Cancer Data Initiative Hub Explore Dashboard Tutorial

Your National Cancer Institute. Driving Cancer Breakthroughs. (Open Captions)
![Your National Cancer Institute. Driving Cancer Breakthroughs. [Extended Version]](https://i.ytimg.com/vi/qL2Ovw21oDA/hqdefault.jpg?sqp=-oaymwEjCNACELwBSFryq4qpAxUIARUAAAAAGAElAADIQj0AgKJDeAE=&rs=AOn4CLDzNVyiXytT8reoy7Pw-wzm0JbSow)
Your National Cancer Institute. Driving Cancer Breakthroughs. [Extended Version]

Your National Cancer Institute. Driving Cancer Breakthroughs.

